Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 7

Complete if Known	
Application Number	09/776,936
Filing Date	December 22, 1998
First Named Inventor	Scott Miller
Group Art Unit	1621
Examiner Name	Kumar, Shailendra
Attorney Docket Number	BAYER-0006-P01

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	A1	4,546,191		Nishiyama et al.	10-08-1985
	A2	6,380,218		Marafat et al.	04-03-2002
	A3	6,525,046		Cirillo et al.	02-25-2003
	A4	6,500,863		Jin et al.	12-31-2002
	A5	6,040,339		Yoshida et al.	03-21-2000
	A6	6,150,415		Hammock et al.	11-21-2000
	A7	6,178,399		Takebayashi et al.	01-23-2001
	A8	6,187,799		Wood et al.	02-13-2001
	A9	7,625,915		Dumas et al.	12-01-2002

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	B1	DE	3529247	A1	Bayer AG	11-20-1986		A9
	B2	WO	90/02112		The Nutrasweet Company	03-08-1990		
	B3	EP	0690344	A1	Konica Corporation	01-03-1996		
	B4	WO	97/09973	A1	The Regents Of The University Of California	3-20-1997		
	B5	WO	98/20868	A1	The Picower Institute of Medical Research	05-22-1998		
	B6	WO	98/45268		Pfizer Products, Inc.	10-15-1998		
	B7	WO	99/28305	A1	E. I. Du Pont de Nemours & Co.	06-10-1999		
	B8	WO	00/43366	A1	Kirin Beer Kabushiki Kaisha	07-27-2000		A9
	B9	WO	00/56331	A1	Vertex Pharmaceuticals, Inc.	09-28-2000		
	B10	WO	02/14331		The University of Kansas	02-21-2002		
	B11	WO	02/062763	A2	Bayer Corporation	8-15-2002		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 7

Complete if Known	
Application Number	09/776,936
Filing Date	December 22, 1998
First Named Inventor	Scott Miller
Group Art Unit	1621
Examiner Name	Kumar, Shailendra
Attorney Docket Number	BAYER-0006-P01

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Office[3]	Number[4]	Kind Code[5] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	B12	WO	02/083628	A1	Boehringer Ingelheim Pharmaceuticals Inc	10-24-2002		
	B13	WO	02/085857	A2	Bayer Corporation	10-31-2002		
	B14	WO	02/085859	A1	Bayer Corporation	10-31-2002		
	B15	WO	02/092576	A1	Boehringer Ingelheim Pharmaceuticals Inc.	11-21-2002		
	B16	WO	03/099771	A2	Novartis AG	12-04-2003		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C1	ADJEI et al., "A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)," Meeting: 2005 ASCO Annual Meeting, Category: Developmental Therapeutics: Molecular Therapeutics, Subcategory: Antiangiogenic or Antimetastatic agents, Abstract No. 4510	
	C2	AHAMD et al., "Kinase inhibition with BAY 43-9006 in renal cell carcinoma," Clinical Cancer Research, Vol. 10, 6388s-6392s, 15 Sept. 2004	
	C3	AUCLAIR, et al., "BAY 43-9006 (Sorafenib) is a potent inhibitor of FLT3 tyrosine kinase signaling and proliferation in AML cells," 96th Annual Meeting, April 16-20, 2005, Anaheim/Orange County, CA	
	C4	BANKSTON, D. ET AL. "A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer" Organic Proc. Research Development, 2002, Vol. 6, No. 6, pp. 777-781	
	C5	BLANCO, "p38 MAPK signaling cascades: ancient roles and new functions," Bioassays, 22:637-645, 2000	
	C6	BOLLAG, G ET AL.,"Raf pathway inhibitors in oncology" Curr. Opin. Invest. Drugs 2003, 4(12), 1436-1441.	
	C7	CAMPBELL et al., "Increasing complexity of Ras signaling," *Oncogene*, (1998) 17, 1395-1413	
	C8	CARTER et al, "Anti-tumor efficacy of the orally active raf kinase inhibitor BAY 43-9006 in human tumor xenograft models," #4954, XP-001145482	
	C9	CHANG et al., "BAY 43-9006 (Sorafenib) inhibitors ectopic (s.c.) and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis," 96th Annual Meeting, April 16-20, 2005, Anaheim/Orange County, CA	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 7

Complete if Known	
Application Number	09/776,936
Filing Date	December 22, 1998
First Named Inventor	Scott Miller
Group Art Unit	1621
Examiner Name	Kumar, Shailendra
Attorney Docket Number	BAYER-0006-P01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [2]
	C10	CLARK et al., "Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors," *Clin. Cancer Res.*, 2005:11(15), 1 August 2005, 5472-5480	
	C11	DANSON et al., "Improving outcomes in advanced malignant melanoma," *Drugs*, 2005, 65(6):733-743	
	C12	DEGRENDELE, H: "Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors" Clin. Colorectal Cancer 2003, 3(1), 16-18.	
	C13	DUMAS, J. "Protein Kinase Inhibitors from the Urea Class" Curr. Opin. Drug Discov. Dev. 2002, 5(5), 715-724.	
	C14	DUMAS, J. ET AL., "Recent Developments in the Discovery of Protein Kinase Inhibitors from the Urea Class" Current Opinion Drug Discovery Development 2004, Vol. 7 No. 5, pp. 600-616.	
	C15	DUMAS, J. ET AL., "Synthesis and Pharmacological Characterization of a Potent, Orally Active p38 Kinase Inhibitor" Bioorganic Medical Chemistry Letters 2002, Vol. 12, pp. 1559.	
	C16	DUMAS, J. ET AL., "Discovery of a New Class of p38 Kinase Inhibitors" Bioorg. Med. Chem. Lett. 2000, 10 (18), 2047.	
	C17	EISEN et al., "Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients," Meeting: *2005 ASCO Annual Meeting*, Category: Melamona, Subcategory: Melamona, Abstract No. 7508	
	C18	EISENHAUER et al., "Impact of new non-cytotoxics in the treatment in ovarian cancer," Int. J. Gynecol Cancer, 2001, 11 (Suppl. 1), 68-72	
	C19	ESCUDIER et al., "Randomized phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)," Meeting: *2005 ASCO Annual Meeting*, Category: Genitourinary Cancer, Subcategory: Kidney Cancer, Abstract No. 4510	
	C20	Facts and Comparisons, 1994, 2703-2705	
	C21	GARCIA-LOPEZ et al., "New routes for the synthesis of pyrrolo[3,2-d]- and -[2,3-d]pyrimidine systems starting from a common pyrrole derivative," *Journal of the Chemical Society*, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1978), (5), 483-7	
	C22	HANSON, "Inhibitors of p38 kinase," *Expert Opinion on Therapeutic Patents*, July 1997, vol. 7, no. 7, pp. 729-733(5)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 7

Complete if Known	
Application Number	09/776,936
Filing Date	December 22, 1998
First Named Inventor	Scott Miller
Group Art Unit	1621
Examiner Name	Kumar, Shailendra
Attorney Docket Number	BAYER-0006-P01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C23	HEIM et al., "Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006," *International Journal of Clinical Pharmacology and Therapeutics*, Vol. 41, No. 12/2003 (616-617)	
	C24	HOTTE ETAL,, "BAY 43-9006: early clinical data in patients with advanced solid malignancies" Curr. Pharm. Design 2002, 8(25), 2249-2253.	
	C25	HUBBARD, "Oncogenic mutations in B-Raf: some losses yield gains," Skirball Institute of Biomolecular Medicine and Department of Pharmacology, New York University School of Medicine, New York, NY	
	C26	Internal Medicine, 4th Edition, 1994, pp. 699-715	
	C27	KEMPTER et al., "Synthese potentieller Pflanzenschutz- und Schädlingsbekämpfungsmittel aus substituierten Anilinen," Pädagosische Hochschule, Eingegangen am 1.7.1982, 101-120	
	C28	KHIRE, U. ET AL., " Omega-Carboxypyridyl Substituted Ureas as Raf Kinase Inhibitors: SAR of the Amide Substituent" Bioorganic Medical Chemistry Letters, 2004, Vol. 14, pp. 783-786.	
	C29	LEE, JT., "BAY-43-9006 (Bayer/Onyx). Curr Opin Invest Drugs (2003) 4(6):757-763.	
	C30	LOWINGER, T. B. ET AL., "Discovery of a Novel Class of Potent Raf Kinase inhibitors: Structure Activity Relationships" Clinical Cancer Research 2000, 6(suppl.) 335.	
	C31	LOWINGER, T. B., "Design and Discovery of Small Molecules Targeting Raf-1 Kinase" Curr. Pharm. Design 2002, 8 (25), 2269.	
	C32	LYONS et al., "Discovery of a novel Raf kinase inhibitor," *Endocrine-Related Cancer*, (2001) 8, 219-225	
	C33	MADWED et al., "Pharmacological Evaluation of BIRB 796, a selective inhibitor of P38 MAP kinase (MAPK), in animal models of endotoxic shock, inflammation and arthritis," Inflammation Res., 50:S184, 2001	
	C34	MOELLING et al., "Signal transuction as target of gene therapy," Institute of Medical Virology, University of Zürich, *Recent Results in Cancer Research*, Vol. 142, pp. 63-71	
	C35	MOORE et al., "Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors," *Annals of Oncology*, 16:1688-1694, 2005	
	C36	MROSS ET AL., "Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors" International Journal of Clinical Pharmacology Ther. 2003, 41(12), 618-619.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 7

Complete if Known	
Application Number	09/776,936
Filing Date	December 22, 1998
First Named Inventor	Scott Miller
Group Art Unit	1621
Examiner Name	Kumar, Shailendra
Attorney Docket Number	BAYER-0006-P01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C37	MURPHY et al., "BAY 43-9006 controls tumor growth through inhibition of vascular development," 96th Annual Meeting, April 16-20, 2005, Anaheim/Orange County, CA	
	C38	NICKEL et al., "Carboxylic acid analogues of suramin, potential filaricides," *Indian Journal of Chemistry*, Vol. 30B, February 1991, p. 182-187	
	C39	PANKA et al., "BAY 43-9006 induces apoptosis in melanoma cell lines," 96th Annual Meeting, April 16-20, 2005, Anaheim/Orange County, CA	
	C40	WILHELM, S. M. et al., "A Novel Diphenylurea Raf-1 Kinase Inhibitor (RKI) Blocks the Raf/Mek/Erk Pathway in Tumor Cells," Proceedings of the American Association for Cancer Research, March 2001, Vol. 42	
	C41	REDMAN, A. M. ET AL., "P38 Kinase Inhibitors for the Treatment of Arthritis and Osteoporosis: Thienyl, Furyl and Pyrrolyl Ureas" Bioorganic Medical Chemistry Letters, 2001, Vol. 11 No. 1, pp. 9	
	C42	REGAN et al., "Pyrazole urea-based inhibitors of P38 MAP kinase: from lead compound to clinical candidate," J. Med. Chem. 45:2994-3008, 2002	
	C43	RICHLY et al., "Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer," International Journal of Clinical Pharmacology and Therapeutics, Vol. 42, No. 11/204 (650-651)	
	C44	RICHLY, H ET AL., "A Phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors" Int. Journal Clinical Pharmacology Therapeutics, 2003, Vol. 41, No. 12, pp. 620-621.	
	C45	RIEDL et al., "Potent Raf Kinase Inhibitors from the Diphenylurea Class: Structure Activity Relationships," 2001, Proc. Amer. Assoc. Can. Res., Vol. 42 No. 923	
	C46	SIU ET AL., "Phase I study of oral Raf-1 kinase inhibitor BAY 43-9006 in combination with gemcitabine in patients with advanced solid tumors" 2003, 39th ASCO meeting, Chicago, IL Abstract 828.	
	C47	SMITH et al., "Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach." Bioorganic & Medicinal Chemistry Letters, 11 (2001) 2775-2778	
	C48	SORBERA, L.A. ET AL., "Oncolytic Raf kinase inhibitor" Drugs Future 2002, Vol. 27, pp.1141-1147.	
	C49	SPRONSEN ET AL., "Novel treatment strategies in clear-cell metastatic renal cell carcinoma," 2005, Anti-Cancer Drugs, Vol. 16, pp. 709-717	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 7

Complete if Known	
Application Number	09/776,936
Filing Date	December 22, 1998
First Named Inventor	Scott Miller
Group Art Unit	1621
Examiner Name	Kumar, Shailendra
Attorney Docket Number	BAYER-0006-P01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C50	STRUMBERG et al., "Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors," Journal of Clinical Oncology, February 2005, Vol. 23, No. 5, pp. 965-972	
	C51	STRUMBERG ET AL., "Results of phase I pharmacokinetic and pharmacodynamic studies of the raf kinase inhibitor BAY 43-9006 in patients with solid tumors," International Journal of Clinical Pharmacology and Therapeutics, 2002, Vol. 40, No. 12, pp. 580-581	
	C52	THAIMATTAM ET AL., "3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies," Bioorganic & Medicinal Chemistry, 2004, Vol. 12, pp. 6415-6425	
	C53	THOMPSON ET AL., "Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery," *Current Opinion Pharmacology*, Aug 2005, Vol. 5, No. 4, pp. 350-356	
	C54	WAN ET AL., "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF," Cell, 2004, Vol. 116, pp. 855-867	
	C55	HANNO ET AL., "Substructure #1," pp/ 1-107, 1996	
	C56	WILHELM, S. M ET AL., "BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis" Cancer Res. 2004, 64(19), 7099-7109.	
	C57	Wilson, Keith et al., "The structural basis for the specificity of pyrimidinylimidazole inhibitors of p38 MAP Kinase" XP-002103155	
	C58	Wisaner et al., "Analogues of platelet activating factor. 7. Bis-aryl amide and bis-aryl urea receptor antagonists of PAF," *J. Med. Chem.*, 1992, 35, 4779-4789	
	C59	Wright et al., "Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1," *Oncology*, 2005 Apr, 19(4):499-502	
	C60	GEIGER, T. ET AL., "Antitumor Activity of a C-raf Antisense Oligonucleotide in Combination with Standard Chemotherapeutic Agents against Various Human Tumors Transplanted Subcutaneously into Nude Mice", July 1997, Vol. 3, p.1179-1185	
	C61	HANSON, G. J. ET AL., "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis",	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 7

Complete if Known	
Application Number	09/776,936
Filing Date	December 22, 1998
First Named Inventor	Scott Miller
Group Art Unit	1621
Examiner Name	Kumar, Shailendra
Attorney Docket Number	BAYER-0006-P01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C62	CUNNINGHAM, C. C. ET AL., "A Phase I Trial of H-ras Antisense Oligonucleotide ISIS 2503 Administered as a Continuous Intravenous Infusion in Patients with Advanced Carcinoma", 2001 American Cancer Society, Volume 92, Number 5, pages 1265-1271.	
	C63	IWADATE, Y. ET AL., "Intra-arterial ACNU, CDDP chemotherapy for brain metastases from lung cancer: comparison of cases with and without intra-arterial mannitol infusion, *Neurol. Surg.*, (1993) Vol. 21, No. 6, pp. 513-518	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.